Linked Life Data

11181147

Source:http://linkedlifedata.com/resource/pubmed/id/11181147

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2001-2-22
pubmed:abstractText
This prospective, multicenter, open-label study was designed to determine the antiretroviral activity and safety of a 4-drug regimen: 1000 mg indinavir every 8 h with 200 mg nevirapine, 40 mg stavudine, and 150 mg lamivudine, each given twice daily in amprenavir-experienced subjects. The primary end points of the study were the human immunodeficiency virus (HIV) RNA level and CD4 cell count responses. Fifty-six subjects were enrolled and were changed from amprenavir-containing regimens to the 4-drug regimen. Overall, at week 48, 33 (59%) of 56 subjects had HIV RNA levels <500 copies/mL (intent-to-treat analysis, where missing values equal > or =500 copies/mL) and CD4 cell counts increased by 94 cells/mm(3) from baseline. Subjects who had previously taken amprenavir combination therapy were more likely to experience virologic failure than those who had taken amprenavir monotherapy (odds ratio, 7.7; P=.0012). In this study, most subjects who had taken amprenavir-based regimens and who changed to a 4-drug regimen achieved subsequent durable virologic suppression.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0022-1899
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
183
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
715-21
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:11181147-Adult, pubmed-meshheading:11181147-Anti-HIV Agents, pubmed-meshheading:11181147-CD4 Lymphocyte Count, pubmed-meshheading:11181147-Carbamates, pubmed-meshheading:11181147-Cross-Over Studies, pubmed-meshheading:11181147-Dose-Response Relationship, Drug, pubmed-meshheading:11181147-Female, pubmed-meshheading:11181147-HIV Infections, pubmed-meshheading:11181147-Humans, pubmed-meshheading:11181147-Indinavir, pubmed-meshheading:11181147-Lamivudine, pubmed-meshheading:11181147-Male, pubmed-meshheading:11181147-Nevirapine, pubmed-meshheading:11181147-Odds Ratio, pubmed-meshheading:11181147-Prospective Studies, pubmed-meshheading:11181147-RNA, Viral, pubmed-meshheading:11181147-Safety, pubmed-meshheading:11181147-Stavudine, pubmed-meshheading:11181147-Sulfonamides, pubmed-meshheading:11181147-Time Factors, pubmed-meshheading:11181147-Treatment Outcome, pubmed-meshheading:11181147-Viral Load
pubmed:year
2001
pubmed:articleTitle
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
pubmed:affiliation
Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA. rgulick@med.cornell.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II